Revier’s €6m Seed Left Legacy Holders With 57.6% While New Investors Built a 29.9% Block

Revier Therapeutics launched with a €6 million seed financing, but the latest shareholder list does not show a clean founder reset or a new-investor majority. The 11 August 2026 register records 43,428 shares. Holders that were already in the company before the June capital increase still account for 25,000 shares, or 57.6% of the total. KHAN Technology Transfer Fund II and Revier Invest Heidelberg together hold 12,982 shares, or 29.9%.

That is the useful distinction behind the funding headline. Revier has added a sizeable institutional block around its cardiometabolic drug programme while the earlier coalition remains the simple majority on the latest nominal share count. The list also records a 2,130-share AD Box GmbH position as an ownership transfer. It does not disclose the issue price, valuation, investor-by-investor cash contribution or the governance rights attached to the holdings.

The €6m announcement and the €43,428 register measure different things

Revier’s 25 August announcement says the company raised €6 million in seed financing led by KHAN Technology Transfer Fund II. High-Tech Gründerfonds, VORNvc and private investors participated through Revier Invest Heidelberg. The company says the money will take class IIa histone deacetylase (HDAC) inhibitors through preclinical work for heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD).

An independent 26 August account from Informationsdienst Wissenschaft describes the same €6 million round, the Heidelberg research origin and the preclinical-to-clinical objective. Neither public announcement translates the funding into a German nominal-capital figure.

The register does. Each share in the latest list has €1 nominal value, and the company’s recorded capital is therefore €43,428. That figure is not a proxy for the €6 million raised. A German company can issue shares at a premium, and the public materials do not state the price paid per share or whether any financing instruments sit outside the shareholder list.

The arithmetic is a diligence frame, not a valuation calculation. The €6 million headline describes the financing announced by the company. The €43,428 figure describes the latest registered nominal capital. Treating the latter as cash raised would confuse the legal share unit with the financing price.

This is similar to the distinction in Callosum’s filed preferred issue, where the registered cash amount and the public dollar headline answer different questions. Revier’s list gives a clear ownership denominator, but not the premium or contractual terms that connect that denominator to the financing amount.

The legacy coalition crossed the financing window with its majority intact

The history explains why the latest list is not a simple new-money takeover. A 9 November 2023 shareholder list recorded €25,000 of capital. Backs Holding held 12,500 shares, Qr Holding 3,750, KHAN Fund I 3,750, Songox 2,500 and Norbert Frey 2,500. By the 13 March 2025 list, Michael Alexander Nolan held 3,750 shares after a transfer from Backs, while the other principal positions remained visible.

The 23 February 2026 list added 375 shares for High-Tech Gründerfonds IV through a capital increase, lifting the nominal total to €25,375. The 23 April list then recorded €25,563 after VORNvc entered with 188 shares. The register also shows DS-Projekte Verwaltungs GmbH receiving 1,222 shares through transfers from Nolan, Backs, Qr Holding, KHAN Fund I, Songox and Frey in the June list.

Those steps matter because they separate two mechanisms. Some capital was created through new shares for investors such as HTGF IV and VORNvc. The DS-Projekte position was assembled through transfers. The older shareholder group did not disappear when these new lines appeared. Between the April and August states, the nominal denominator expanded sharply, but the earlier coalition still represents 25,000 shares in the latest list.

The 57.6% calculation is a simple share-count comparison based on the group that existed before the June capital increase. It does not prove that the same people act together, that they hold identical voting rights beyond the ordinary share count or that they retain every contractual board right. It does show that the announced seed did not replace the earlier majority with a filed majority for new investors.

KHAN II and Revier Invest arrived as a block, not as a majority

The latest list gives KHAN Technology Transfer Fund II 5,172 shares and Revier Invest Heidelberg 7,810. Together they hold 12,982 of 43,428 shares, or 29.9%. Their combined position is large enough to be the central new-investor block, but it remains well below the simple majority held by the earlier group.

The same list shows HTGF IV at 2,126 shares and VORNvc at 1,190. Their positions began in the earlier capital increases and then grew in the latest state. AD Box GmbH appears with 2,130 shares, marked “Anteilübergang”, or ownership transfer. That label establishes the recorded legal movement, but it does not identify the beneficial owner behind the vehicle. The public record therefore supports a description of several new or enlarged lines around the seed, not a single fund-controlled cap table.

The ownership pattern has a practical consequence for governance. New investors have enough capital at risk to demand information, protective provisions or board access in the financing documents. The register alone cannot say whether those rights exist, whether the vehicles vote together or how management appointments are allocated. It does establish the baseline against which any later governance claim should be tested.

The financing is aimed at preclinical risk, not near-term revenue

Revier says its class IIa HDAC inhibitor programme targets HFpEF and ASCVD, two cardiovascular indications where preclinical evidence still has to translate into clinical development. The company’s public announcement describes a path through preclinical studies and the functions needed to reach clinical testing. Informationsdienst Wissenschaft adds that the company grew out of work connected to the German Centre for Cardiovascular Research in Heidelberg and names the scientific and operating leadership.

That use of proceeds changes the commercial reading of the round. Revier is financing a development milestone, not reporting a product launch or a recurring-revenue base. The investors therefore face biological, regulatory and trial-execution risk before any commercial validation. The €6 million can fund the next evidence step, but neither public source states a clinical outcome, a partnering payment or a revenue forecast.

The coalition structure also spreads that risk across different types of holder. KHAN II and Revier Invest provide the largest identifiable new block. HTGF IV and VORNvc already sit in the capital history. The earlier holders retain the majority share-count position and remain exposed to the same preclinical programme. Employees and scientific partners are operationally tied to the programme, but the sources do not assign them an economic stake.

The next filings will decide whether the block becomes control

The current evidence establishes a financing event and a post-event nominal share map. It does not establish the price per share, the full €6 million allocation, the valuation, the beneficial ownership of Revier Invest or AD Box, or any board-reserved matters. Those are not footnote details. They determine whether the 29.9% new-investor block is simply a substantial minority or carries contractual influence beyond its share count.

The next useful documents are the subscription or notarial terms behind the June and July capital steps, any amended articles or shareholders’ agreement, and the next shareholder list. They should show whether the nominal increase was paired with a large premium, whether the named vehicles received different classes or rights, and whether the AD Box transfer has a disclosed economic owner.

For now, the defensible conclusion is narrower and more useful than the launch headline: Revier’s €6 million seed built a 29.9% block for KHAN II and Revier Invest while the legacy coalition stayed above 57% of the latest nominal register. The company has changed its financing base, but the filing does not show a control handover.

Sources: Revier Therapeutics seed announcement, Informationsdienst Wissenschaft independent report.